🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Focal Onset Seizures

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) NCT05716100Phase 398 sites📍 Little Rock📍 Downey📍 Los Angeles Xenon Pharmaceuticals Inc. · Tests: XEN1101, Placebo A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures NCT07233239Phase 124 sites📍 Phoenix📍 La Jolla📍 New Haven Jazz Pharmaceuticals · Tests: CBD-OS Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures NCT07594119Phase 313 sites📍 Huntsville📍 Bentonville📍 Colorado Springs Rapport Therapeutics Inc. · Tests: RAP-219, RAP-219, Placebo Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain NCT06716801n/a1 site📍 Paris Aziende Chimiche Riunite Angelini Francesco S.p.A · Tests: Cenobamate Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy NCT05518578Phase 210 sites📍 Jacksonville📍 Miami📍 Randwick Supernus Pharmaceuticals, Inc. · Tests: SPN-817 An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures NCT06908356Phase 211 sites📍 Phoenix📍 Miami Lakes📍 Bethesda Praxis Precision Medicines · Tests: 30mg PRAX-628 Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) NCT05135091Phase 335 sites📍 Birmingham📍 Phoenix📍 Tucson Neurona Therapeutics · Tests: NRTX-1001, NRTX-1001, Sham Comparator Changes in Attentional Control After a Focal Seizure. NCT06466681n/a1 site📍 Lille University Hospital, Lille · Tests: All included subjects Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures NCT07793396n/a1 site📍 Lahore King Edward Medical University · Tests: Eslicarbazepine acetate Epilepsy Learning Healthcare System (ELHS) NCT06265103n/a13 sites📍 Phoenix📍 Los Angeles📍 Los Angeles Epilepsy Foundation of America · Tests: Clinical care and quality improvement Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 NCT07563881Phase 318 sites📍 Birmingham📍 Palmdale📍 Gulf Breeze Rapport Therapeutics Inc. · Tests: RAP-219, RAP-219, Placebo Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables NCT07012148EARLY Phase 13 sites📍 Scottsdale📍 Jacksonville📍 Rochester Mayo Clinic · Tests: UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM) Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement NCT06241924NA1 site📍 Bordeaux University Hospital, Bordeaux · Tests: High Resolution Electroencephalogram (EEG-HR), Stereo-electro-encephalography (SEEG) RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures NCT06798896Phase 263 sites📍 Phoenix📍 Phoenix📍 Tucson Supernus Pharmaceuticals, Inc. · Tests: SPN-817, Placebo A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures NCT07219407Phase 27 sites📍 Boise📍 Rochester📍 New York Rapport Therapeutics Inc. · Tests: RAP-219 REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization NCT06922175n/a10 sites📍 Freiburg im Breisgau📍 Hamburg📍 Kork Aziende Chimiche Riunite Angelini Francesco S.p.A Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology NCT06388161n/a1 site📍 Hangzhou Shen Chun-Hong SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures NCT07141329Phase 21 site📍 Port Charlotte Supernus Pharmaceuticals, Inc. · Tests: SPN-817
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy